Bicara Therapeutics Inc.
BCAX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0002023658
In the last 90 days, Bicara Therapeutics Inc. insiders filed 0 open-market purchases and 1 sale; 172 institutions reported holding it in 13F filings for Q2 2026, worth $2.07B in total; no superinvestor holds it.
- Currency
- USD
- Source
- SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
- Updated
- Nov 10, 2026, 1:21 AM ET
Income statement
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 |
|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 |
| Filing | 10-K | 10-K |
| Reported | Feb 26, 2026 | Mar 27, 2025 |
| Operating expenses | $155.6M | $82.4M |
| Research and development | – | $63.6M |
| Selling, general and administrative | $30.5M | $18.8M |
| Operating income | -$155.6M | -$82.4M |
| Income tax | $217.0K | $180.0K |
| Net income | -$137.9M | -$68.0M |
| EPS, basic | $-2.52 | $-4.05 |
| EPS, diluted | $-2.52 | $-4.05 |
| Weighted shares, basic | 54.7B | 16.8B |
| Weighted shares, diluted | 54.7B | 16.8B |
Balance sheet
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 |
|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 |
| Filing | 10-K | 10-K |
| Reported | Feb 26, 2026 | Mar 27, 2025 |
| Cash and equivalents | $96.7M | $489.7M |
| Short-term investments | $318.1M | – |
| Total current assets | $422.1M | $502.5M |
| Property, plant and equipment | $330.0K | $155.0K |
| Total assets | $431.0M | $510.0M |
| Total current liabilities | $28.9M | $18.0M |
| Total liabilities | $29.5M | $18.1M |
| Shareholders' equity | $401.5M | $491.9M |
Cash flow statement
Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.
| Line item | FY2025 | FY2024 |
|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 |
| Filing | 10-K | 10-K |
| Reported | Feb 26, 2026 | Mar 27, 2025 |
| Operating cash flow | -$106.8M | -$74.8M |
| Capital expenditures | $280.0K | $71.0K |
| Free cash flow | -$107.1M | -$74.8M |
| Stock-based compensation | $15.0M | $7.40M |
| Investing cash flow | -$318.5M | -$9.00K |
| Financing cash flow | $32.3M | $334.0M |
| Net change in cash | -$393.0M | $259.3M |
Shares outstanding
Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.
Notes and known gaps
How these numbers are put together, and what they can't tell you.
- Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
- Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
Known gaps
- Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
- EPS and share counts are as reported at the time, not adjusted for later stock splits.
- For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
- For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
- Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
- Depreciation and amortization is missing for some companies that report it under their own XBRL tags.